BioNexus Gene Lab Corp. Equity Securities, FV-NI, Gain (Loss)
BioNexus Gene Lab Corp. (BGLC) reported Equity Securities, FV-NI, Gain (Loss) of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2026-08-14
- BioNexus Gene Lab Corp. equity securities, fv-ni, gain (loss) for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- BioNexus Gene Lab Corp. equity securities, fv-ni, gain (loss) for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- BioNexus Gene Lab Corp. equity securities, fv-ni, gain (loss) for the quarter ending 2025-12-31 was -$28.26K.
- BioNexus Gene Lab Corp. equity securities, fv-ni, gain (loss) for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- BioNexus Gene Lab Corp. equity securities, fv-ni, gain (loss) for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- BioNexus Gene Lab Corp. equity securities, fv-ni, gain (loss) for fiscal 2024 was $69.48K, a 77.34% decline from fiscal 2023.
- BioNexus Gene Lab Corp. equity securities, fv-ni, gain (loss) for fiscal 2023 was $306.61K.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | -$28.26K derived: sum of 3 quarters · filed 2026-08-14 | -$28.26K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-15 | -$28.26K derived: sum of 2 quarters · filed 2026-05-15 | -$28.26K derived: sum of 3 quarters · filed 2026-05-15 | -$4.51K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$28.26K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | -$28.26K derived: sum of 2 quarters · filed 2026-04-14 | -$4.51K derived: sum of 3 quarters · filed 2026-08-14 | $0.00 10-K · filed 2026-04-14 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 | $23.74K derived: sum of 2 quarters · filed 2026-08-14 | $28.26K 10-Q · filed 2025-11-14 | -$145.35K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $23.74K 10-Q · filed 2026-08-14 | $28.26K 10-Q · filed 2026-08-14 | -$145.35K derived: sum of 3 quarters · filed 2026-08-14 | -$75.58K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $4.51K 10-Q · filed 2026-05-15 | -$169.09K derived: sum of 2 quarters · filed 2026-05-15 | -$99.33K derived: sum of 3 quarters · filed 2026-05-15 | -$10.79K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$173.61K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | -$103.84K derived: sum of 2 quarters · filed 2026-04-14 | -$15.31K derived: sum of 3 quarters · filed 2026-04-14 | $69.48K 10-K · filed 2026-04-14 |
| 2024-09-30 | $69.77K 10-Q · filed 2025-11-14 | $158.30K derived: sum of 2 quarters · filed 2025-11-14 | $243.08K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $88.53K 10-Q · filed 2025-08-18 | $173.32K 10-Q · filed 2025-08-18 | ||
| 2024-03-31 | $84.78K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $306.61K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |